Skip to main content
Advertisement

Main menu

  • Home
  • Content
    • Current Issue
    • Accepted Manuscripts
    • Article Preview
    • Past Issue Archive
    • Video Articles
    • AJNR Case Collection
    • Case of the Week Archive
    • Case of the Month Archive
    • Classic Case Archive
  • Special Collections
    • AJNR Awards
    • ASNR Foundation Special Collection
    • Most Impactful AJNR Articles
    • Photon-Counting CT
    • Spinal CSF Leak Articles (Jan 2020-June 2024)
  • Multimedia
    • AJNR Podcasts
    • AJNR SCANtastic
    • Trainee Corner
    • MRI Safety Corner
    • Imaging Protocols
  • For Authors
    • Submit a Manuscript
    • Submit a Video Article
    • Submit an eLetter to the Editor/Response
    • Manuscript Submission Guidelines
    • Statistical Tips
    • Fast Publishing of Accepted Manuscripts
    • Graphical Abstract Preparation
    • Imaging Protocol Submission
    • Author Policies
  • About Us
    • About AJNR
    • Editorial Board
    • Editorial Board Alumni
  • More
    • Become a Reviewer/Academy of Reviewers
    • Subscribers
    • Permissions
    • Alerts
    • Feedback
    • Advertisers
    • ASNR Home

User menu

  • Alerts
  • Log in

Search

  • Advanced search
American Journal of Neuroradiology
American Journal of Neuroradiology

American Journal of Neuroradiology

ASHNR American Society of Functional Neuroradiology ASHNR American Society of Pediatric Neuroradiology ASSR
  • Alerts
  • Log in

Advanced Search

  • Home
  • Content
    • Current Issue
    • Accepted Manuscripts
    • Article Preview
    • Past Issue Archive
    • Video Articles
    • AJNR Case Collection
    • Case of the Week Archive
    • Case of the Month Archive
    • Classic Case Archive
  • Special Collections
    • AJNR Awards
    • ASNR Foundation Special Collection
    • Most Impactful AJNR Articles
    • Photon-Counting CT
    • Spinal CSF Leak Articles (Jan 2020-June 2024)
  • Multimedia
    • AJNR Podcasts
    • AJNR SCANtastic
    • Trainee Corner
    • MRI Safety Corner
    • Imaging Protocols
  • For Authors
    • Submit a Manuscript
    • Submit a Video Article
    • Submit an eLetter to the Editor/Response
    • Manuscript Submission Guidelines
    • Statistical Tips
    • Fast Publishing of Accepted Manuscripts
    • Graphical Abstract Preparation
    • Imaging Protocol Submission
    • Author Policies
  • About Us
    • About AJNR
    • Editorial Board
    • Editorial Board Alumni
  • More
    • Become a Reviewer/Academy of Reviewers
    • Subscribers
    • Permissions
    • Alerts
    • Feedback
    • Advertisers
    • ASNR Home
  • Follow AJNR on Twitter
  • Visit AJNR on Facebook
  • Follow AJNR on Instagram
  • Join AJNR on LinkedIn
  • RSS Feeds

AJNR is seeking candidates for the AJNR Podcast Editor. Read the position description.

Review ArticleReview Articles
Open Access

Addictive Illegal Drugs: Structural Neuroimaging

S. Geibprasert, M. Gallucci and T. Krings
American Journal of Neuroradiology May 2010, 31 (5) 803-808; DOI: https://doi.org/10.3174/ajnr.A1811
S. Geibprasert
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
M. Gallucci
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
T. Krings
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • Responses
  • References
  • PDF
Loading

Abstract

SUMMARY: Illegal addictive drugs can lead to functional or structural impairment of the central nervous system. This review provides an overview of the structural imaging findings on CT, MR imaging, and conventional angiography related to chronic and acute abuse of the most commonly abused illegal drugs, including cannabis, organic solvents, and amphetamines and opioids and their respective derivatives. Pathomechanisms include excitotoxicity, which may lead to an acute or subacute leukoencephalopathy, and vascular complications, including vasoconstriction, vasculitis, or hypertension, which may lead to intracranial hemorrhage or ischemia. Because clinical findings alone are often nonspecific, and afflicted patients are unlikely to admit to the substance abuse, the neuroradiologist may play an important role in establishing the diagnosis and, thereby, initiating treatment.

Abbreviations

CB
cannabinoid
5-HT
serotonin (5-hydroxytryptamine)
MCA
middle cerebral artery
MDMA
3,4-methylenedioxymethamphetamine
MRA
MR angiography
PET
positron-emission tomography

Illegal addictive drugs can alter both the function and the structure of the central nervous system.1–3 Functional imaging studies, such as MR spectroscopy, functional MR imaging, single-photon emission tomography, or PET may detect changes in the regional cerebral blood flow, cerebral activity, and neuropharmacologic parameters, such as receptor number and neurotransmitter levels.4,5 These methods are, therefore, of importance in detecting the functional or metabolic impairment following illegal drug abuse. On the other hand, conventional imaging methods (ie, CT, MR imaging, or angiography) will demonstrate the structural damage done to the brain. These structural alterations may be due to acute or chronic toxicity, they may be reversible or irreversible, and their pattern of involvement may be specific or nonspecific for the substance used. Because clinical symptoms are often nonspecific and may mimic other etiologies and because the correct diagnosis is of great importance to prevent further damage to the brain, the neuroradiologist plays a crucial role in raising the suspicion of illegal drug abuse. This review describes the most commonly encountered addictive drug−induced changes to the brain, their pathomechanisms, clinical findings, and, most important, their imaging features, focusing on structural rather than functional imaging studies.

Cannabis

Cannabis or marijuana is the most commonly used illicit drug worldwide.6,7 The major psychoactive compound is δ-9-tetrahydrocannabinol, which is a lipid-soluble substance that causes activation of the CB receptors. The CB receptors are heterogeneously distributed in the brain, with the highest densities in the basal ganglia, substantia nigra, globus pallidus, dentate gyrus of hippocampus, limbic cortices, and cerebellum.8 Smoking is the preferred route of drug delivery, but it can also be taken orally.

Acute effects of cannabis include cognitive dysfunction, memory and time-assessment alterations, motor incoordination, poor executive functions, and sedative effects.9 Cardiovascular changes occur for about 2–3 hours following drug abuse, with an increased heart rate and cardiac output, increased blood pressure in the supine position, and orthostatic hypotension. Chronic use can lead to behavioral changes and seems to increase the risk for developing schizophrenia.

Ischemic strokes related to cannabis have been reported in the literature; however, due to the widespread use of the drug and confounding problems of polydrug abuse, it is difficult and often impossible to establish whether these strokes are truly associated with cannabis or other ingested drugs or are purely coincidental. Vasospasm, orthostatic hypotension, and vasculitis have been proposed as mechanisms in young patients without other vascular risk factors.10 Functional imaging studies, including PET and MR perfusion, in the acute stage of cannabis abuse demonstrate an overall decrease in regional cerebral blood flow in the frontal, parietal, temporal, and occipital lobes,11,12 while transcranial Doppler shows an increased pulsatility index due to increased resistance from vasoconstriction.13 The stroke pattern reported following cannabis ingestion is nonspecific, and imaging findings are indistinguishable from those in strokes of other causes.

Organic Solvents: Inhalants (Toluene)

Toluene or methyl-benzene is a lipid-soluble aromatic hydrocarbon, which is commonly used as a solvent in many industrial products such as paint, paint thinner, glue, or ink. It is widely abused in many countries14,15 due to its widespread availability and low cost. There are hardly any discernible withdrawal symptoms. Long-term occupational exposures, for example, in dry cleaning, aviation, and chemical industries, may lead to chronic intoxication. The lungs rapidly absorb the inhaled toluene into the blood, and the substance subsequently accumulates in the lipid-rich brain.16 Toluene is oxidized into benzolic acid before being conjugated with glycine in the liver to form hippuric acid, which is excreted by the kidneys.

Acute intoxication following inhalation is clinically characterized by reversible behavioral changes, euphoria, headache, and ataxia (afflicted subjects are referred to as “spray heads”). In the acute stage, no alterations are seen on structural imaging; in chronic abusers, however, irreversible neurologic damage with structural alterations will occur.17,18 Findings of toluene-induced chronic toxic encephalopathy include changes in cerebellar and cerebral white matter, with demyelination and gliosis, which leads to cerebellar dysfunction; psychiatric disorders; spasticity; cognitive changes; and secondary Parkinson disease. Symptoms of attention deficit; decline in visual-spatial skills, frontal lobe function, and memory retrieval; hearing and visual loss; and cranial nerve abnormalities may also occur. Long-term exposure will result in brain atrophy, predominantly in the cerebellum, owing to a decline of Purkinje cells in the brain stem at the pontine level and in the hippocampus. There are few reports of optic nerve atrophy.

Abnormal findings on MR imaging are typically seen after at least 4–7 years of chronic inhalant abuse and are irreversible once detected, suggesting that the lesions are related to the accumulative toxic effect of the substance. Diffuse T2 hyperintensities can be seen in the periventricular white matter, centrum semiovale and the cerebellum, internal capsule, and pons. These white matter lesions are concordant with the severity of neurologic deficits and cognitive impairment.14 Atrophy is also often observed and can be seen as dilation of the ventricles; thinning of the corpus callosum; and diffuse atrophy of the hippocampus, cerebellum, cerebrum, and brain stem. In approximately 30%–50% of cases, T2 hypointensities are found in the thalami and basal ganglia. These may be due to disruption of the physiologic axonal iron transport with secondary iron accumulation or to partition of toluene into the brain lipids.15,16,19,20

Amphetamines and Derivatives

Cocaine

Cocaine is a highly addictive drug due to its short biologic half-life and strong reinforcing properties which can lead to compulsive usage.21 The drug can produce local anesthesia by blocking nervous impulses; activate the parasympathetic nervous system by blocking the uptake of catecholamines and by blocking dopamine reuptake; and lead to a short intense euphoria with feelings of elation, increased energy, and alertness. Neurotoxic effects include agitation and seizures. In its most commonly used form (ie, cocaine hydrochloride), it is ingested via mucosal membranes. “Crack,” the alkaloidal freebase of cocaine hydrochloride, can also be smoked.22

Most central nervous system complications induced by cocaine are vascular, with either hemorrhagic or ischemic strokes. Cocaine-related hemorrhages can be either intraparenchymal or subarachnoid and are twice as common as ischemic strokes.22,23 Approximately 40%–50% of patients have an underlying vascular pathology, such as a brain arteriovenous malformation or a brain aneurysm. Ruptures of the arteriovenous malformation or the aneurysm are most likely related to the elevated blood pressure and heart rate from the sympathomimetic effect of the drug (Fig 1).22,24,25 In cases without an underlying vascular pathology, the intraparenchymal hemorrhages are most often located in the basal ganglia and thalamus. Reperfusion hemorrhages from an ischemic stroke can also occur, and the risk of hemorrhage increases with the concomitant use of alcohol.26

Fig 1.
  • Download figure
  • Open in new tab
  • Download powerpoint
Fig 1.

A 19-year-old woman presented with acute onset of headaches to the emergency department. CT demonstrates an intraventricular hemorrhage with a potential parenchymal component close to the right ventricular wall (arrows on CT). Drug screening was positive for alcohol and cocaine. Because approximately half of the patients with intracranial hemorrhage following cocaine abuse have an underlying cause for their hemorrhage, angiography was performed, demonstrating a choroidal arteriovenous malformation fed by the posterior lateral choroidal artery (arrows on angiography) of the posterior cerebral artery, with slightly early venous filling (arrowheads), which was subsequently successfully embolized.

While the pathomechanism of hemorrhagic stroke is straightforward, the causes for ischemic stroke are manifold, including cocaine-induced vasoconstriction, vasculitis (due to unknown additives/impurities), vasospasm, or the direct effects of cocaine on hemostasis. Cocaine enhances the responses of platelets to arachidonic acid, with increased levels of thromboxane, which leads to increased platelet aggregation resulting in concurrent myocardial and cerebral infarction from thrombosis. Cocaine also has procoagulant effects due to depletion of antithrombin III and protein C.27,28 Infarctions often involve the subcortical white matter within the MCA territory; however, they can be present anywhere in the brain. Most interesting, mesencephalic stroke seems to be more frequent when cocaine is used together with other amphetamines.29 MRA may reveal focal narrowing of the main branches of the circulation with associated vessel wall contrast enhancement, which may favor local vasculitis as the causative mechanism (instead of vasospasm or vasoconstriction) (Fig 2). Cerebral atrophy is seen in chronic cocaine abusers in late stages. The frontal lobe is typically most severely affected, followed by the temporal lobes; chronic ischemia may be the underlying pathomechanism responsible for this atrophy.30

Fig 2.
  • Download figure
  • Open in new tab
  • Download powerpoint
Fig 2.

A 23-year-old woman woke up with a complete hemiplegia. Following a positive urine analysis, she admitted having taken considerable amounts of cocaine the night before. MR imaging demonstrates an MCA branch ischemia including involvement of the basal ganglia. T1-weighted postcontrast scans demonstrate abnormal vessel wall enhancement in the right MCA (arrowheads), and the time-of-flight MRA shows some mild irregularities of the distal M1, potentially testifying to acute drug-induced vasculitis as the most likely cause for the ischemia (arrows).

Ecstasy

Ecstasy or MDMA is a drug derived from methamphetamine, which is popular as a party drug because it has both stimulating and mild hallucinatory effects. In the acute phase, the drug users experience euphoria, increased self-confidence, increased sensory perceptions, tachycardia, and hyperthermia.31,32 Trismus or acute psychoses may be present. The effect wears off after 24–48 hours, with patients experiencing muscle aches, depression, fatigue, and decreased concentration.

MDMA causes acute rapid release of 5-HT, which is a potent vasoconstrictor from serotonergic synapses and leads to increased synaptic dopamine levels in several brain areas.33 Although its permanent neurotoxicity is still a matter of debate, there is evidence that stimulation of 5-HT2A receptors in small vessels will lead to prolonged vasospasm and result in necrosis of the involved regions of the brain.34 The occipital cortex and globus pallidus are the most vulnerable brain regions due to the high levels of 5-HT and 5-HT2A receptors.35–37 Ischemia is, therefore, more likely to occur than hemorrhage and often involves small vessels (Fig 3).38

Fig 3.
  • Download figure
  • Open in new tab
  • Download powerpoint
Fig 3.

This young male patient with a subacute onset of hemisensory deficit following ingestion of an unidentified psychoactive designer drug has a small area of cytotoxic edema with fluid-attenuated inversion recovery hyperintensity and decreased apparent diffusion coefficient value in his right mediodorsal thalamus, which is classically supplied by thalamoperforators arising from the distal posterior communicating artery (arrowheads). The time-of-flight MRA at 3T demonstrates a focal narrowing of this artery at the presumed origin of the thalamoperforators supplying the infarcted region (arrows). Drug-induced vasospasm or local vasculitis is presumed to be the cause for his acute ischemia.

Opioids and Derivatives

Heroin is the most commonly abused drug within this group and has the most significant adverse effect on the brain.39 Other derivatives include morphine, hydrocodone, oxycodone, hydromorphine, codeine, and other narcotics such as fentanyl, meperidene, methadone, and opium. Three types of receptors are activated by heroin: Stimulation of the μ opioid receptor will result in analgesic effects, euphoria, respiratory depression, and miosis, while stimulation of the κ and δ opioid receptors causes analgesic, dysphoric, and psychomimetic effects.40 Both acute and chronic effects of heroin on the brain have been described and include neurovascular disorders, leukoencephalopathy, and atrophy.39,41 In addition to these primary or direct effects of heroin on the brain, secondary complications have to be differentiated. These are related to added impurities (either lipophilic additives [“cutting”] or crystalline impurities), and they may also be secondary to associated diseases (such as infections or epilepsy).

Ischemia is the most commonly encountered acute neurovascular complication caused by heroin. The proposed pathomechanisms are manifold (similar to ischemia related to cocaine) and include the following: 1) direct effects of the heroin with reversible vasospasm from stimulation of the vascular smooth muscles by the μ opioid receptors, 2) vasculitis from immune-mediated responses (which may be related to the heroin itself or to impure additives), or 3) embolic events from crystalline impure additives (Fig 4).42,43 Ischemia is more often encountered following intravenous injection compared with other routes such as oral ingestion or inhalation.43 The globus pallidus is the most commonly involved location, and infarcts in this location are present in approximately 5%–10% of chronic heroin abusers.44 In addition to acute ischemia, white matter changes from microvascular disease can be seen in chronic heroin abusers. Diffuse, symmetric, and bilateral T2 hyperintensities may be perceived in the subcortical or periventricular white matter, compatible with vascular leukoencephalopathy. However, these changes are commonly not as severe as in chronic cocaine abusers.

Fig 4.
  • Download figure
  • Open in new tab
  • Download powerpoint
Fig 4.

Acute areas of ischemia in both the anterior and middle cerebral artery territories involving predominantly the gray matter as a result of a diffuse vasculitis with a “pearl-and-string” sign along the anterior cerebral artery, with an acute occlusion of the pericallosal artery (arrows) and luminal irregularities in multiple different vessels in a patient with intravenous heroine abuse. Whether the described vasculitic pattern is due to vasospasm (ie, the primary effect of the opioid), immune-mediated responses against the heroin or added impurities, or a primary infectious process of the vessel wall cannot be differentiated.

An important complication is heroin-induced leukoencephalopathy, which is exclusively seen after heroin inhalation (“chasing the dragon”) and is never seen following heroin injection or oral ingestion.45–47 In heroin inhalation, the drug is heated over tinfoil and the emerging vapors are inhaled. Presumably due to activation of an as-of-yet-unknown substance, an acute leukoencephalopathy may occur with generalized brain edema (Fig 5). More common than this acute form, though, is the chronic subacute encephalopathy, which results in spongiform degeneration of the white matter, especially the corticospinal and solitary tracts, with associated multivacuolar degeneration of oligodendrocytes on histopathology (Figs 6 and 7).48,49

Fig 5.
  • Download figure
  • Open in new tab
  • Download powerpoint
Fig 5.

Acute (upper row) and chronic (after 6 months) effects following heroin inhalation (chasing the dragon). In the acute phase, a diffuse edematous swelling of the white matter is present both supra- and infratentorially. On follow-up after 6 months, the patient demonstrated mental retardation and persistent psychosis. CT demonstrates bilateral degeneration of the white matter with concomitant widening of the ventricles.

Fig 6.
  • Download figure
  • Open in new tab
  • Download powerpoint
Fig 6.

Chronic effects of heroin inhalation (typical form). Diffuse white matter changes are present, with sparing of the dentate nuclei and the cerebellar cortex and involvement of the corticospinal tracts and medial lemnisci. Clinically, this patient presented with a progressive spastic paraparesis.

Fig 7.
  • Download figure
  • Open in new tab
  • Download powerpoint
Fig 7.

Chronic effects of heroin inhalation (atypical form). This patient presented with psychosis and progressive dementia 20 years after she discontinued heroin inhalation (which she performed for nearly 10 years). Although not proved, the vacuolic degeneration speaks in favor of heroin-induced leukoencephalopathy, which is predominant in the white matter of both temporal lobes.

From a clinical point of view, the subacute heroin-induced leukoencephalopathy progresses from cerebellar symptoms to extrapyramidal symptoms, spasms, and hypotonic tetraparesis, eventually leading to the patient's death. The findings on MR imaging consist of T2 hyperintense lesions, predominantly in the white matter of the cerebellar hemispheres and posterior limb of the internal capsule (with sparing of the anterior limb), and the subcortical white matter, predominantly in the posterior aspect, only extending to the anterior aspect in severe cases or late stages. While in acute stages, diffusion restriction is present, testifying to cytotoxic edema, the subacute stages will demonstrate an increased diffusion due to myelin breakdown.

Infections are the most important secondary complication of heroin abuse. CNS infections may occur following endocarditis due to nonsterile conditions associated with intravenous drug abuse. Up to 45%–58% of drug users with endocarditis will eventually develop neurologic complications, including septic emboli resulting in brain abscesses, and mycotic aneurysms caused by inflammatory destruction of the vessel wall.50,51 The most common responsible organism is Staphylococcus aureus.52 Brain abscesses have the well-known and characteristic thin rim-like contrast enhancement surrounding a core that is hypointense on T1 and hyperintense on T2-weighted scans and that demonstrates diffusion restriction.53,54 Extensive perifocal edema is present. Mycotic aneurysms can occasionally be seen on MRA; however, due to their small size and their peripheral location, they are better detected on conventional cerebral angiography and are seen as multiple small fusiform dilations involving the peripheral cortical arteries or perforators, with proximal and distal irregular narrowing and contrast stagnation in the capillary phase.

Conclusions

The main pathomechanisms related to the abuse of addictive drugs are ischemia, hemorrhage, and leukoencephalopathy related to excitotoxicity of the drug or its derivatives. While some imaging patterns are specific for a certain drug, others are overlapping. Clinical findings, especially in the acute setting, are often nonspecific, requiring the neuroradiologist to include drug-induced causes into the differential diagnoses of hemorrhage, ischemia, and diffuse white matter changes, especially in young patients.

Indicates open access to non-subscribers at www.ajnr.org

References

  1. 1.↵
    1. Fowler JS,
    2. Volkow ND,
    3. Kassed CA,
    4. et al
    . Imaging the addicted human brain. Sci Pract Perspect 2007;3:4–16
    PubMed
  2. 2.↵
    1. Gatley SJ,
    2. Volkow ND
    . Addiction and imaging of the living human brain. Drug Alcohol Depend 1998;51:97–108
    CrossRefPubMed
  3. 3.↵
    1. Lingford-Hughes AR,
    2. Davies SJ,
    3. McIver S,
    4. et al
    . Addiction. Br Med Bull 2003;65:209–22
    Abstract/FREE Full Text
  4. 4.↵
    1. Magalhaes AC
    . Functional magnetic resonance and spectroscopy in drug and substance abuse. Top Magn Reson Imaging 2005;16:247–51
    CrossRefPubMed
  5. 5.↵
    1. Mena JC,
    2. Cuellar H,
    3. Vargas D,
    4. et al
    . PET and SPECT in drug and substance abuse. Top Magn Reson Imaging 2005;16:253–56
    CrossRefPubMed
  6. 6.↵
    1. Moussouttas M
    . Cannabis use and cerebrovascular disease. Neurologist 2004;10:47–53
    CrossRefPubMed
  7. 7.↵
    1. Chang L,
    2. Chronicle EP
    . Functional imaging studies in cannabis users. Neuroscientist 2007;13:422–32
    Abstract/FREE Full Text
  8. 8.↵
    1. Quickfall J,
    2. Crockford D
    . Brain neuroimaging in cannabis use: a review. J Neuropsychiatry Clin Neurosci 2006;18:318–32
    CrossRefPubMed
  9. 9.↵
    1. Iversen L
    . Cannabis and the brain. Brain 2003;126:1252–70
    Abstract/FREE Full Text
  10. 10.↵
    1. Mateo I,
    2. Pinedo A,
    3. Gomez-Beldarrain M,
    4. et al
    . Recurrent stroke associated with cannabis use. J Neurol Neurosurg Psychiatry 2005;76:435–37
    Abstract/FREE Full Text
  11. 11.↵
    1. Mathew RJ,
    2. Wilson WH,
    3. Humphreys DF,
    4. et al
    . Regional cerebral blood flow after marijuana smoking. J Cereb Blood Flow Metab 1992;12:750–58
    PubMed
  12. 12.↵
    1. O'Leary DS,
    2. Block RI,
    3. Koeppel JA,
    4. et al
    . Effects of smoking marijuana on brain perfusion and cognition. Neuropsychopharmacology 2002;26:802–16
    CrossRefPubMed
  13. 13.↵
    1. Herning RI,
    2. Better WE,
    3. Tate K,
    4. et al
    . Marijuana abusers are at increased risk for stroke: preliminary evidence from cerebrovascular perfusion data. Ann N Y Acad Sci 2001;939:413–15
    PubMed
  14. 14.↵
    1. Aydin K,
    2. Sencer S,
    3. Ogel K,
    4. et al
    . Single-voxel proton MR spectroscopy in toluene abuse. Magn Reson Imaging 2003;21:777–85
    CrossRefPubMed
  15. 15.↵
    1. Yamanouchi N,
    2. Okada S,
    3. Kodama K,
    4. et al
    . White matter changes caused by chronic solvent abuse. AJNR Am J Neuroradiol 1995;16:1643–49
    Abstract
  16. 16.↵
    1. Aydin K,
    2. Sencer S,
    3. Demir T,
    4. et al
    . Cranial MR findings in chronic toluene abuse by inhalation. AJNR Am J Neuroradiol 2002;23:1173–79
    Abstract/FREE Full Text
  17. 17.↵
    1. King MD
    . Neurological sequelae of toluene abuse. Hum Toxicol 1982;1:281–87
    PubMed
  18. 18.↵
    1. Lazar RB,
    2. Ho SU,
    3. Melen O,
    4. et al
    . Multifocal central nervous system damage caused by toluene abuse. Neurology 1983;33:1337–40
    Abstract/FREE Full Text
  19. 19.↵
    1. Unger E,
    2. Alexander A,
    3. Fritz T,
    4. et al
    . Toluene abuse: physical basis for hypointensity of the basal ganglia on T2-weighted MR images. Radiology 1994;193:473–76
    PubMed
  20. 20.↵
    1. Kamran S,
    2. Bakshi R
    . MRI in chronic toluene abuse: low signal in the cerebral cortex on T2-weighted images. Neuroradiology 1998;40:519–21
    CrossRefPubMed
  21. 21.↵
    1. Williams MJ,
    2. Adinoff B
    . The role of acetylcholine in cocaine addiction. Neuropsychopharmacology 2008;33:1779–97
    CrossRefPubMed
  22. 22.↵
    1. Brown E,
    2. Prager J,
    3. Lee HY,
    4. et al
    . CNS complications of cocaine abuse: prevalence, pathophysiology, and neuroradiology. AJR Am J Roentgenol 1992;159:137–47
    PubMed
  23. 23.↵
    1. Nolte KB,
    2. Gelman BB
    . Intracerebral hemorrhage associated with cocaine abuse. Arch Pathol Lab Med 1989;113:812–13
    PubMed
  24. 24.↵
    1. McEvoy AW,
    2. Kitchen ND,
    3. Thomas DG
    . Intracerebral haemorrhage and drug abuse in young adults. Br J Neurosurg 2000;14:449–54
    CrossRefPubMed
  25. 25.↵
    1. Pozzi M,
    2. Roccatagliata D,
    3. Sterzi R
    . Drug abuse and intracranial hemorrhage. Neurol Sci 2008;29(suppl 2):S269–270
    PubMed
  26. 26.↵
    1. Levine SR,
    2. Brust JC,
    3. Futrell N,
    4. et al
    . Cerebrovascular complications of the use of the “crack” form of alkaloidal cocaine. N Engl J Med 1990;323:699–704
    CrossRefPubMed
  27. 27.↵
    1. Krendel DA,
    2. Ditter SM,
    3. Frankel MR,
    4. et al
    . Biopsy-proven cerebral vasculitis associated with cocaine abuse. Neurology 1990;40:1092–94
    Abstract/FREE Full Text
  28. 28.↵
    1. Nolte KB,
    2. Brass LM,
    3. Fletterick CF
    . Intracranial hemorrhage associated with cocaine abuse: a prospective autopsy study. Neurology 1996;46:1291–96
    Abstract/FREE Full Text
  29. 29.↵
    1. Kaufman MJ,
    2. Levin JM,
    3. Ross MH,
    4. et al
    . Cocaine-induced cerebral vasoconstriction detected in humans with magnetic resonance angiography. JAMA 1998;279:376–80
    CrossRefPubMed
  30. 30.↵
    1. Rojas R,
    2. Riascos R,
    3. Vargas D,
    4. et al
    . Neuroimaging in drug and substance abuse. Part I. Cocaine, cannabis, and ecstasy. Top Magn Reson Imaging 2005;16:231–38
    CrossRefPubMed
  31. 31.↵
    1. Hurley RA,
    2. Reneman L,
    3. Taber KH
    . Ecstasy in the brain: a model for neuroimaging. J Neuropsychiatry Clin Neurosci 2002;14:125–29
    CrossRefPubMed
  32. 32.↵
    1. Morgan MJ
    . Ecstasy (MDMA): a review of its possible persistent psychological effects. Psychopharmacology (Berl) 2000;152:230–48
    CrossRefPubMed
  33. 33.↵
    1. Green AR,
    2. Mechan AO,
    3. Elliott JM,
    4. et al
    . The pharmacology and clinical pharmacology of 3,4-methylenedioxymethamphetamine (MDMA, “ecstasy”). Pharmacol Rev 2003;55:463–508
    Abstract/FREE Full Text
  34. 34.↵
    1. Reneman L,
    2. Habraken JB,
    3. Majoie CB,
    4. et al
    . MDMA (“Ecstasy”) and its association with cerebrovascular accidents: preliminary findings. AJNR Am J Neuroradiol 2000;21:1001–07
    Abstract/FREE Full Text
  35. 35.↵
    1. Henry JA,
    2. Jeffreys KJ,
    3. Dawling S
    . Toxicity and deaths from 3,4-methylenedioxymethamphetamine (“ecstasy”). Lancet 1992;340:384–87
    CrossRefPubMed
  36. 36.↵
    1. Spatt J,
    2. Glawar B,
    3. Mamoli B
    . A pure amnestic syndrome after MDMA (“ecstasy”) ingestion. J Neurol Neurosurg Psychiatry 1997;62:418–19
    FREE Full Text
  37. 37.↵
    1. Squier MV,
    2. Jalloh S,
    3. Hilton-Jones D,
    4. et al
    . Death after ecstasy ingestion: neuropathological findings. J Neurol Neurosurg Psychiatry 1995;58:756
    FREE Full Text
  38. 38.↵
    1. Bae SC,
    2. Lyoo IK,
    3. Sung YH,
    4. et al
    . Increased white matter hyperintensities in male methamphetamine abusers. Drug Alcohol Depend 2006;81:83–88
    CrossRefPubMed
  39. 39.↵
    1. Borne J,
    2. Riascos R,
    3. Cuellar H,
    4. et al
    . Neuroimaging in drug and substance abuse. Part II. Opioids and solvents. Top Magn Reson Imaging 2005;16:239–45
    CrossRefPubMed
  40. 40.↵
    1. Trescot AM,
    2. Datta S,
    3. Lee M,
    4. et al
    . Opioid pharmacology. Pain Physician 2008;11(2 suppl):S133–153
    PubMed
  41. 41.↵
    1. Buttner A,
    2. Mall G,
    3. Penning R,
    4. et al
    . The neuropathology of heroin abuse. Forensic Sci Int 2000;113:435–42
    CrossRefPubMed
  42. 42.↵
    1. Brust JC,
    2. Richter RW
    . Stroke associated with addiction to heroin. J Neurol Neurosurg Psychiatry 1976;39:194–99
    Abstract/FREE Full Text
  43. 43.↵
    1. Volkow ND,
    2. Valentine A,
    3. Kulkarni M
    . Radiological and neurological changes in the drug abuse patient: a study with MRI. J Neuroradiol 1988;15:288–93
    PubMed
  44. 44.↵
    1. Andersen SN,
    2. Skullerud K
    . Hypoxic/ischaemic brain damage, especially pallidal lesions, in heroin addicts. Forensic Sci Int 1999;102:51–59
    CrossRefPubMed
  45. 45.↵
    1. Bartlett E,
    2. Mikulis DJ
    . Chasing “chasing the dragon” with MRI: leukoencephalopathy in drug abuse. Br J Radiol 2005;78:997–1004
    Abstract/FREE Full Text
  46. 46.↵
    1. Keogh CF,
    2. Andrews GT,
    3. Spacey SD,
    4. et al
    . Neuroimaging features of heroin inhalation toxicity: “chasing the dragon. ” AJR Am J Roentgenol 2003;180:847–50
    PubMed
  47. 47.↵
    1. Offiah C,
    2. Hall E
    . Heroin-induced leukoencephalopathy: characterization using MRI, diffusion-weighted imaging, and MR spectroscopy. Clin Radiol 2008;63:146–52
    CrossRefPubMed
  48. 48.↵
    1. Schiffer D,
    2. Brignolio F,
    3. Giordana MT,
    4. et al
    . Spongiform encephalopathy in addicts inhaling pre-heated heroin. Clin Neuropathol 1985;4:174–80
    PubMed
  49. 49.↵
    1. Wolters EC,
    2. van Wijngaarden GK,
    3. Stam FC,
    4. et al
    . Leucoencephalopathy after inhaling “heroin” pyrolysate. Lancet 1982;2:1233–37
    PubMed
  50. 50.↵
    1. Pruitt AA,
    2. Rubin RH,
    3. Karchmer AW,
    4. et al
    . Neurologic complications of bacterial endocarditis. Medicine (Baltimore) 1978;57:329–43
    PubMed
  51. 51.↵
    1. Ramsey RG,
    2. Gunnar RM,
    3. Tobin JR Jr.
    . Endocarditis in the drug addict. Am J Cardiol 1970;25:608–18
    CrossRefPubMed
  52. 52.↵
    1. Tunkel AR,
    2. Pradhan SK
    . Central nervous system infections in injection drug users. Infect Dis Clin North Am 2002;16:589–605
    CrossRefPubMed
  53. 53.↵
    1. Falcone S,
    2. Post MJ
    . Encephalitis, cerebritis, and brain abscess: pathophysiology and imaging findings. Neuroimaging Clin N Am 2000;10:333–53
    PubMed
  54. 54.↵
    1. Leuthardt EC,
    2. Wippold FJ 2nd.,
    3. Oswood MC,
    4. et al
    . Diffusion-weighted MR imaging in the preoperative assessment of brain abscesses. Surg Neurol 2002;58:395–402,discussion 402
    CrossRefPubMed
  • Copyright © American Society of Neuroradiology
View Abstract
PreviousNext
Back to top

In this issue

American Journal of Neuroradiology: 31 (5)
American Journal of Neuroradiology
Vol. 31, Issue 5
1 May 2010
  • Table of Contents
  • Index by author
Advertisement
Print
Download PDF
Email Article

Thank you for your interest in spreading the word on American Journal of Neuroradiology.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Addictive Illegal Drugs: Structural Neuroimaging
(Your Name) has sent you a message from American Journal of Neuroradiology
(Your Name) thought you would like to see the American Journal of Neuroradiology web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Cite this article
S. Geibprasert, M. Gallucci, T. Krings
Addictive Illegal Drugs: Structural Neuroimaging
American Journal of Neuroradiology May 2010, 31 (5) 803-808; DOI: 10.3174/ajnr.A1811

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
0 Responses
Respond to this article
Share
Bookmark this article
Addictive Illegal Drugs: Structural Neuroimaging
S. Geibprasert, M. Gallucci, T. Krings
American Journal of Neuroradiology May 2010, 31 (5) 803-808; DOI: 10.3174/ajnr.A1811
del.icio.us logo Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Purchase

Jump to section

  • Article
    • Abstract
    • Abbreviations
    • Cannabis
    • Organic Solvents: Inhalants (Toluene)
    • Amphetamines and Derivatives
    • Opioids and Derivatives
    • Conclusions
    • References
  • Figures & Data
  • Info & Metrics
  • Responses
  • References
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • MicroRNA-mRNA networks are dysregulated in opioid use disorder postmortem brain: further evidence for opioid-induced neurovascular alterations
  • Cannabis-related Stroke: Myth or Reality?
  • Crossref (90)
  • Google Scholar

This article has been cited by the following articles in journals that are participating in Crossref Cited-by Linking.

  • Advances in clinical and molecular understanding of the FMR1 premutation and fragile X-associated tremor/ataxia syndrome
    Randi Hagerman, Paul Hagerman
    The Lancet Neurology 2013 12 8
  • Imaging Spectrum of CNS Vasculitis
    Ahmed Abdel Khalek Abdel Razek, Hortensia Alvarez, Stephen Bagg, Sherif Refaat, Mauricio Castillo
    RadioGraphics 2014 34 4
  • Neuropathology of substance use disorders
    Jean Lud Cadet, Veronica Bisagno, Christopher Mark Milroy
    Acta Neuropathologica 2014 127 1
  • Review: The neuropathology of drug abuse
    A. Büttner
    Neuropathology and Applied Neurobiology 2011 37 2
  • Cannabis-related Stroke
    Valérie Wolff, Jean-Paul Armspach, Valérie Lauer, Olivier Rouyer, Marc Bataillard, Christian Marescaux, Bernard Geny
    Stroke 2013 44 2
  • Imaging Patterns of Toxic and Metabolic Brain Disorders
    Arthur M. de Oliveira, Matheus V. Paulino, Ana P. F. Vieira, Alexander M. McKinney, Antonio J. da Rocha, Germana T. dos Santos, Claudia da Costa Leite, Luis F. de Souza Godoy, Leandro T. Lucato
    RadioGraphics 2019 39 6
  • Your Brain on Drugs: Imaging of Drug-related Changes in the Central Nervous System
    Benita Tamrazi, Jeevak Almast
    RadioGraphics 2012 32 3
  • Solvents and Parkinson disease: A systematic review of toxicological and epidemiological evidence
    Edward A. Lock, Jing Zhang, Harvey Checkoway
    Toxicology and Applied Pharmacology 2013 266 3
  • Cannabis-associated Myocardial Infarction in a Young Man with Normal Coronary Arteries
    Christopher J. Hodcroft, Melissa C. Rossiter, Ashesh N. Buch
    The Journal of Emergency Medicine 2014 47 3
  • Post-mortem whole body computed tomography of opioid (heroin and methadone) fatalities: frequent findings and comparison to autopsy
    Sebastian Winklhofer, Eddie Surer, Garyfalia Ampanozi, Thomas Ruder, Paul Stolzmann, Marina Elliott, Andrea Oestreich, Thomas Kraemer, Michael Thali, Hatem Alkadhi, Wolf Schweitzer
    European Radiology 2014 24 6

More in this TOC Section

  • Mechanisms of Healing in Coiled Intracranial Aneurysms: A Review of the Literature
  • Ultra-High-Field MR Neuroimaging
  • 4D-CTA in Neurovascular Disease: A Review
Show more Review Articles

Similar Articles

Advertisement

Indexed Content

  • Current Issue
  • Accepted Manuscripts
  • Article Preview
  • Past Issues
  • Editorials
  • Editor's Choice
  • Fellows' Journal Club
  • Letters to the Editor
  • Video Articles

Cases

  • Case Collection
  • Archive - Case of the Week
  • Archive - Case of the Month
  • Archive - Classic Case

Special Collections

  • AJNR Awards
  • ASNR Foundation Special Collection
  • Most Impactful AJNR Articles
  • Photon-Counting CT
  • Spinal CSF Leak Articles (Jan 2020-June 2024)

More from AJNR

  • Trainee Corner
  • Imaging Protocols
  • MRI Safety Corner

Multimedia

  • AJNR Podcasts
  • AJNR Scantastics

Resources

  • Turnaround Time
  • Submit a Manuscript
  • Submit a Video Article
  • Submit an eLetter to the Editor/Response
  • Manuscript Submission Guidelines
  • Statistical Tips
  • Fast Publishing of Accepted Manuscripts
  • Graphical Abstract Preparation
  • Imaging Protocol Submission
  • Evidence-Based Medicine Level Guide
  • Publishing Checklists
  • Author Policies
  • Become a Reviewer/Academy of Reviewers
  • News and Updates

About Us

  • About AJNR
  • Editorial Board
  • Editorial Board Alumni
  • Alerts
  • Permissions
  • Not an AJNR Subscriber? Join Now
  • Advertise with Us
  • Librarian Resources
  • Feedback
  • Terms and Conditions
  • AJNR Editorial Board Alumni

American Society of Neuroradiology

  • Not an ASNR Member? Join Now

© 2025 by the American Society of Neuroradiology All rights, including for text and data mining, AI training, and similar technologies, are reserved.
Print ISSN: 0195-6108 Online ISSN: 1936-959X

Powered by HighWire